In the first half of the year, BeiGene (688235.SH, stock price 145.48 yuan, market value 2002.31 billion yuan) has been the "leader" in China's new drug industry for more than 2 years, but has not yet achieved profitability, despite reducing losses by over 40% but multiple peers have achieved profitability. BeiGene is facing increasing "peer pressure". On August 29th, BeiGene released its 2024 semi annual report, achieving a revenue of 11.996 billion yuan in the first half of the year, a year-on-year increase of 65.44%; The net profit attributable to the parent company was 2.877 billion yuan, with a year-on-year decrease of 44.87% in losses and a loss of 5.219 billion yuan in the same period last year.